FDA Public Meeting: Patient-Focused Drug Development Meeting

Date: August 25, 2026 Time: 10:00 a.m. – 4:30 p.m. ET Location:

Event Location

Attend In Person or Online
Virtual: via webcast
In Person: FDA White Oak Campus

10903 New Hampshire Avenue
Building 31, Room 1503
Silver Spring, MD 20993
United States

On August 25, 2026, the U.S. Food and Drug Administration (FDA) is hosting a hybrid public meeting on Patient-Focused Drug Development for Nonhealing Chronic Wounds. This meeting will provide FDA the opportunity to hear directly from patients, patient representatives, and care partners about their experiences with nonhealing chronic wounds, including how the wounds and associated wound care affect their daily life, what matters most to them, their current approaches for managing or treating their nonhealing chronic wounds, and what they consider when determining whether to participate in a clinical trial.

There will be three sessions focused on: (1) health effects and daily impacts, (2) current approaches to treatment, and (3) perspectives on clinical trials. For each topic, a brief initial patient panel discussion will begin the dialogue. This will be followed by a facilitated discussion inviting comments from other patient and care partner participants in the audience. Panelists are also welcome to participate in the facilitated discussion.

This webpage will be updated as meeting materials are developed.

Panelists

If you are a patient or care partner interested in providing comments as part of the panel discussion, please indicate so during registration by July 3, 2026. A member of the PFDD Staff will contact you via email. Panelists will be confirmed prior to the meeting.

Related Information

CDER Patient-Focused Drug Development

• Content current as of:

  04/06/2026

Source